Today's Hours: 10:00am - 6:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Sujata P. Sawarkar, Vandana S. Nikam, Shariq Syed, editors.
    Summary: This book illustrates the significance and relevance of immunotherapy in modern-day therapeutics. Focusing on the application of immunotherapy in oncology, neurodegenerative and autoimmune diseases, it discusses the drug delivery systems, and pre-clinical and clinical methodologies for immunotherapy-based drugs. It also comprehensively reviews various aspects of immunotherapy, such as regulatory affairs, quality control, safety, and pharmacovigilance. Further, the book discusses the in vitro validation of therapeutic strategies prior to patient application and management of immunotherapy-related side effects and presents case studies demonstrating the design and development (pre-clinical to clinical) of immunotherapy for various diseases. It also describes various design considerations and the scale-up synthesis of immunotherapeutics and screening methods. Lastly, it explores the important aspect of cost-effectiveness and rational immunotherapy strategies.

    Contents:
    Chapter 1. Immunotherapy
    a Concept
    Chapter 2. Immunotherapy in Cancer
    Immune Checkpoint Inhibitors; changing Oncology treatment paradigm
    Chapter 3. Vaccines as Immunotherapy
    Chapter 4. Immunotherapy for Autoimmune Diseases
    Chapter 5. Immunotherapy in neurodegenerative disorders
    Chapter 6. Companion diagnostics and clinical biomarkers for immunotherapy
    Chapter 7. Novel Drug Delivery Systems for Immunotherapeutics
    Chapter 8. Discovery, Screening Methods, Design Considerations and Scale-up aspects of Immunotherapeutic Drugs
    Chapter 9. Pharmacokinetics, Pharmacodynamics, and Toxicology aspects of Immunotherapeutics
    Chapter 10. Regulatory Affairs and Intellectual Property Rights in Immunotherapeutics
    Chapter 11. Future immunotherapy challenges and perspectives.
    Digital Access Springer 2021
  • Article
    Spellacy WN, Cruz AC, Buhi WC, Birk SA.
    Am J Obstet Gynecol. 1978 Jul 15;131(6):637-42.
    Twenty-nine women in premature labor were randomly assigned to a ritodrine (N = 14) or placebo (N = 15) treatment group. Thirteen serial blood samples were drawn during the first 12 hours of therapy by intravenous drug infusion and they were analyzed for a variety of metabolic substances. There was a significant increase in the blood glucose level in the ritodrine group after one hour and this persisted for the 12 hours of intravenous drug treatment. Plasma insulin levels similarly did not increase in the placebo but significantly rose in the ritodrine group by 30 minutes, peaked at 2 1/2 hours, and remained elevated throughout the infusion. There were no significant differences between levels of plasma glucagon, cholesterol triglyceride, human placental lactogen, or human chorionic gonadotropin in the two treatment groups. Ritodrine caused significant maternal and fetal tachycardia. Its use in women with carbohydrate abnormalities should be monitored carefully. The increased glucose levels may lead to an increased fetal weight.
    Digital Access Access Options